📊 RXST Key Takeaways
Is RxSight, Inc. (RXST) a Good Investment?
RxSight exhibits strong gross margins (76.6%) indicating product-market fit, but persistent operating losses (-35.8% margin) and negative free cash flow (-$19.3M) create an unsustainable business model. With only $19.9M in cash against annual burn rates, the company faces critical liquidity concerns within 12 months unless operations reach profitability.
Why Buy RxSight, Inc. Stock? RXST Key Strengths
- Exceptional gross margin of 76.6% demonstrates strong pricing power and product demand in ophthalmic sector
- Clean balance sheet with zero long-term debt and $275.7M stockholders' equity
- Strong liquidity ratios (10.95x current, 9.75x quick) provide near-term operational flexibility
RXST Stock Risks: RxSight, Inc. Investment Risks
- Declining revenue (-3.9% YoY) combined with -$38.9M net losses indicates fundamental business deterioration
- Negative operating cash flow (-$15.5M) and free cash flow (-$19.3M) create unsustainable cash burn relative to $19.9M available cash
- Worsening diluted EPS (-33.8% YoY decline) with no visible path to profitability in near term
Key Metrics to Watch
- Operating cash flow inflection and path to positive cash generation
- Quarterly revenue stabilization or recovery and gross margin maintenance
- Cash runway depletion rate and potential need for external financing or strategic restructuring
RxSight, Inc. (RXST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.95x current ratio provides a solid financial cushion.
RXST Profit Margin, ROE & Profitability Analysis
RXST vs Market Sector: How RxSight, Inc. Compares
How RxSight, Inc. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RxSight, Inc. Stock Overvalued? RXST Valuation Analysis 2026
Based on fundamental analysis, RxSight, Inc. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RxSight, Inc. Balance Sheet: RXST Debt, Cash & Liquidity
RXST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: RxSight, Inc.'s revenue has grown significantly by 519% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.41 indicates the company is currently unprofitable.
RXST Revenue Growth, EPS Growth & YoY Performance
RXST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $30.3M | -$6.1M | $-0.16 |
| Q2 2025 | $33.6M | -$6.1M | $-0.16 |
| Q1 2025 | $29.5M | -$8.2M | $-0.20 |
| Q3 2024 | $22.2M | -$6.1M | $-0.16 |
| Q2 2024 | $20.8M | -$6.1M | $-0.16 |
| Q1 2024 | $17.5M | -$9.1M | $-0.25 |
| Q3 2023 | $12.6M | -$12.4M | $-0.35 |
| Q2 2023 | $11.4M | -$13.2M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RxSight, Inc. Dividends, Buybacks & Capital Allocation
RXST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for RxSight, Inc. (CIK: 0001111485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RXST
What is the AI rating for RXST?
RxSight, Inc. (RXST) has an AI rating of SELL with 80% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RXST's key strengths?
Claude: Exceptional gross margin of 76.6% demonstrates strong pricing power and product demand in ophthalmic sector. Clean balance sheet with zero long-term debt and $275.7M stockholders' equity.
What are the risks of investing in RXST?
Claude: Declining revenue (-3.9% YoY) combined with -$38.9M net losses indicates fundamental business deterioration. Negative operating cash flow (-$15.5M) and free cash flow (-$19.3M) create unsustainable cash burn relative to $19.9M available cash.
What is RXST's revenue and growth?
RxSight, Inc. reported revenue of $134.5M.
Does RXST pay dividends?
RxSight, Inc. does not currently pay dividends.
Where can I find RXST SEC filings?
Official SEC filings for RxSight, Inc. (CIK: 0001111485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RXST's EPS?
RxSight, Inc. has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RXST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RxSight, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RXST stock overvalued or undervalued?
Valuation metrics for RXST: ROE of -14.1% (sector avg: 15%), net margin of -29.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RXST stock in 2026?
Our dual AI analysis gives RxSight, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RXST's free cash flow?
RxSight, Inc.'s operating cash flow is $-15.5M, with capital expenditures of $3.8M. FCF margin is -14.4%.
How does RXST compare to other Market stocks?
Vs Default sector averages: Net margin -29.0% (avg: 12%), ROE -14.1% (avg: 15%), current ratio 10.95 (avg: 1.8).